Medullary Thyroid Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Medullary Thyroid Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major medullary thyroid cancer markets reached a value of US$ 141.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 405.1 Million by 2034, exhibiting a growth rate (CAGR) of 10.06% during 2024-2034.

The medullary thyroid cancer market has been comprehensively analyzed in IMARC's new report titled "Medullary Thyroid Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Medullary thyroid cancer is a relatively rare form of oncological disease that originates from the parafollicular C cells in the thyroid gland responsible for producing calcitonin, a hormone that regulates calcium levels in the body. It is often a hereditary condition, occurring either as a familial syndrome or sporadically. The symptoms of this illness manifest as a lump or nodule in the neck. However, due to the tumor's production of calcitonin, some individuals suffering from the ailment might also experience flushing or diarrhea. Numerous other indications can include hoarseness, trouble swallowing, breathing difficulties, etc. The diagnosis of medullary thyroid cancer involves a combination of physical examination and blood tests to check for elevated levels of calcitonin and carcinoembryonic antigen (CEA). The healthcare provider will further conduct imaging studies, such as ultrasound and magnetic resonance imaging (MRI), to ascertain the size and location of the tumor. A fine-needle aspiration biopsy is also done to confirm the diagnosis.

The escalating incidence of genetic mutations in the RET gene, which affect various cellular processes, including cell growth, differentiation, and survival, is primarily driving the medullary thyroid cancer market. In addition to this, the inflating utilization of effective treatment regimens, such as tyrosine kinase inhibitors and calcimimetics, to manage the condition and curtail its progression is also creating a positive outlook for the market. Moreover, the widespread adoption of physical and speech therapies, particularly post-surgery, to aid in restoring vocal function, enhancing swallowing abilities, and improving the overall quality of life of patients is further propelling the market growth. Apart from this, the rising usage of minimally invasive surgical techniques, on account of their numerous advantages like prioritizing precision and reducing recovery times, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted radiation therapies, since they specifically disrupt malignant cells while sparing healthy tissue in the surrounding region, is also augmenting the market growth. Furthermore, the escalating demand for gene therapy, wherein therapeutic genetic material is introduced into cells with an aim to correct or replace the mutated or dysfunctional genes causing the tumor, is expected to drive the medullary thyroid cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the medullary thyroid cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for medullary thyroid cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the medullary thyroid cancer market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the medullary thyroid cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the medullary thyroid cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current medullary thyroid cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the medullary thyroid cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the medullary thyroid cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the medullary thyroid cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of medullary thyroid cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of medullary thyroid cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of medullary thyroid cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with medullary thyroid cancer across the seven major markets?
What is the size of the medullary thyroid cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of medullary thyroid cancer?
What will be the growth rate of patients across the seven major markets?

Medullary Thyroid Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for medullary thyroid cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the medullary thyroid cancer market?
What are the key regulatory events related to the medullary thyroid cancer market?
What is the structure of clinical trial landscape by status related to the medullary thyroid cancer market?
What is the structure of clinical trial landscape by phase related to the medullary thyroid cancer market?
What is the structure of clinical trial landscape by route of administration related to the medullary thyroid cancer market?